A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer

József Horti, Anders Widmark, Arnulf Stenzl, Miriam H. Federico, Raymond P. Abratt, Nick Sanders, Gillian M. Pover, István Bodrogi

Research output: Contribution to journalArticle

37 Citations (Scopus)

Fingerprint Dive into the research topics of 'A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences